PUBLISHER: The Business Research Company | PRODUCT CODE: 1895258
PUBLISHER: The Business Research Company | PRODUCT CODE: 1895258
Bioprocessing refers to the use of living cells or their components (such as enzymes, bacteria, or yeast) to obtain desired products, particularly in the production of pharmaceuticals, biofuels, chemicals, and food ingredients. It is an essential part of biotechnology manufacturing, especially for complex biological therapies that cannot be synthesized chemically. Bioprocessing is primarily used in the biopharmaceutical industry to manufacture biologics such as monoclonal antibodies, vaccines, hormones, enzymes, and cell and gene therapies. These products are used across a wide range of medical treatments, including cancer, autoimmune disorders, infectious diseases, and rare genetic conditions.
The global bioprocessing market reached a value of nearly $62,344.10 million in 2024, having grown at a compound annual growth rate (CAGR) of 12.93% since 2019. The market is expected to grow from $62,344.10 million in 2024 to $122,677.10 million in 2029 at a rate of 14.50%. The market is then expected to grow at a CAGR of 13.45% from 2029 and reach $230,550.77 million in 2034.
Expansion Of Pharmaceutical And Biotechnology Industries
During the historic period, the bioprocessing market was mainly driven by the expansion of pharmaceutical and biotechnology industries. As pharmaceutical and biotech firms grew in scale and scope, the demand for efficient, reliable bioprocessing systems, such as fermenters, bioreactors, downstream purification, and automation, rose significantly. These technologies enabled mass production of biologics, vaccines, and biosimilars, helping meet rising healthcare demands while ensuring quality and regulatory compliance. For instance, in June 2025, according to the Eliquent Japan, a regulatory consulting firm supporting biotech and pharmaceutical companies, published by MixOnline (a magazine), Japan's pharmaceutical market for FY2024 (April 2024 - March 2025) reached 11.4874 trillion yen ($76.82 billion, based on NHI price), representing a 1% increase from the previous year. This marks the second consecutive year the market has remained above 11 trillion yen ($73.56 billion), achieving a new record high in fiscal year terms. Furthermore, in May 2025, according to a presentation by India Brand Equity Foundation (IBEF), a trust established by the Government of India to promote and showcase India's business, economic, and investment potential globally, India's biotechnology industry expanded from $ 10 billion in 2015 to $ 130 billion in 2024, with expectations to reach US$ 150 billion by 2025. Therefore, throughout the historic period, the growth of pharmaceutical and biotechnology industries served as a principal driver for the bioprocessing market.
Expansion of Automated Cell and Gene Therapy Manufacturing in Emerging Markets
Companies in the market are focusing on expanding automated cell and gene therapy manufacturing capabilities in emerging markets to meet growing global demand and reduce production costs. Automation enhances process consistency, scalability, and regulatory compliance, which are critical for complex therapies. This expansion allows localized manufacturing, improving accessibility and reducing supply chain challenges. As a result, it drives increased adoption of advanced bioprocessing technologies tailored for high-efficiency, large-scale production. For example, in October 2024, Terumo Blood and Cell Technologies, a US-based medical technology company, expanding its offerings in Latin America to help bring automated manufacturing to cell and gene therapy companies in Brazil, Colombia and Mexico. Cell and gene therapies are a rapidly advancing field and hold the potential to treat diseases and transform lives. Affordability and the ability to scale these treatments in the manufacturing process are key factors that make automated technologies promising in helping cell and gene therapies touch more patients' lives. This is especially important in Latin America, where there is a heavy reliance on government healthcare systems.
The global bioprocessing market is fairly fragmented, with a large number of small players operating in the market. The top ten competitors in the market made up to 23.04% of the total market in 2024.
Bioprocessing Global Market Opportunities And Strategies To 2034 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global bioprocessing market as it emerges from the COVID-19 shut down.
Where is the largest and fastest-growing market for bioprocessing? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The bioprocessing market global report from The Business Research Company answers all these questions and many more.
The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider bioprocessing market; and compares it with other markets.